Browse News
Filter News
Found 573,065 articles
-
Janssen Pharmaceutical of Johnson & Johnson released new long-term data from the open-label period of its Phase III VOYAGE 1 clinical trial.
-
According to the report, the majority of the cuts will occur in the company’s Human Health Division and are expected to begin Jan. 3 and conclude Jan. 16, 2020.
-
BioSpace Movers & Shakers, Oct. 18
10/18/2019
Pharma, biotech and medtech companies strengthen their executive ranks and boards with this week's Movers & Shakers. -
Genentech’s Xofluza Approved for People at High Risk of Developing Flu-Related Complications
10/18/2019
Genentech’s flu medication Xofluza won a new indication for the treatment of acute, uncomplicated influenza in people 12 years of age and older who have been symptomatic for less than 48 hours and are at high risk of flu-related complications. -
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
As the first part of a six-part series describing the hottest careers in the biopharma industry, we discussed the rewarding career of genetic counselor. Now, let’s take a look at the high in demand biopharma careers of biostatistician and biometrician.
-
New research by researchers at the University of California Los Angeles into the role of astrocytes, star-shaped brain cells, in the disease, may lead to new treatment strategies.
-
A competitor, Invitae Corporation, presented a poster at the American Society of Human Genetics (ASHG) annual meeting that essentially accuses 23andMe’s tests of completing missing a cancer-causing DNA variant in some ethnic groups.
-
Assure to Attend Upcoming Investor Conferences
10/18/2019
Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services, announced that management will participate in the following upcoming investor conferences:
-
Novan Further Expands its Proprietary Nitric Oxide Platform
10/18/2019
Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company has submitted a request for a pre-IND meeting with the U.S. Food and Drug Administration (FDA) for new product candidate, SB207
-
Growth of Ventricular Drainage Devices Market to Be Impacted by the Rising Adoption of Robot-assisted Neurosurgery | Technavio
10/18/2019
The report, global ventricular drainage devices market, has been added to Technavio’s catalog. It provides a comprehensive analysis of the market, including its global and regional market share as well as market segmentation based on product and geography for the forecast period 2019-2023.
-
Cyclo Therapeutics Announces Its Support for The Firefly Fund’s Newborn Screening Program
10/18/2019
Cyclo Therapeutics, Inc. (OTCQB:CTDH), formerly CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that the company has provided a grant to The Firefly Fund in support of its newborn screening program for Niemann-Pick Disease Type C.
-
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
10/18/2019
ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced the closing of its previously announced underwritten public offering of 9,090,909 ordinary shares at a price to the public of $5.50 per share.
-
Inscopix and Astellas Initiate Collaboration to Study Neural Activity Patterns in Preclinical Models of Psychiatric Disorders
10/18/2019
Inscopix has entered into a research collaboration with Astellas Research Institute of America LLC, a subsidiary of Astellas Pharma Inc., to develop novel preclinical drug screening assays for psychiatric disorders.
-
Growth of Liver Cancer Drugs Market to Be Impacted by the Introduction of Precision Cancer Medicine | Technavio
10/18/2019
The report, liver cancer drugs market 2019-2023, has been added to Technavio's catalog. It provides a comprehensive analysis of the market, including its global and regional market share as well as market segmentation based on type (immunotherapy and targeted therapy) and geography (APAC, Americas, and EMEA) for the forecast period 2019-2023.
-
Catabasis Pharmaceuticals to Present at the Child Neurology Society 48th Annual Meeting
10/18/2019
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that results from the Phase 2 MoveDMD trial and open-label extension with edasalonexent in boys affected by Duchenne muscular dystrophy (DMD) will be presented at the Child Neurology Society 48th Annual Meeting to be held October 23-26 in Charlotte, North Carolina.
-
Prof. Reggie Edgerton To Be Honored For Groundbreaking Neuroscience Research
10/18/2019
The Shirley Ryan AbilityLab today hosts a symposium in Chicago to celebrate the pioneering work of UCLA's Prof. Reggie Edgerton.
-
FDA Clears ORTHO™ Sera ID-MTS for Use on the ORTHO VISION® Analyzer
10/18/2019
Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, today announced that ORTHO™ Sera, a suite of extended antigen phenotyping, has been cleared by the U.S. Food and Drug Administration for use on the ORTHO VISION® Analyzer.
-
SOPHiA GENETICS Reaches New Analytical Heights With Its Whole Exome Solution
10/18/2019
SOPHiA GENETICS, leader in Data-Driven Medicine, announced today at the American Society of Human Genetics Annual Meeting (ASHG) the release of the new version of SOPHiA Whole Exome Solution.
-
Philadelphia's Integral Molecular Opens New Research Center in Response to Upsurge in Antibody Discovery Partnerships
10/18/2019
Integral Molecular, the industry leader in membrane protein solutions, has expanded its research facility to a second location to accommodate an upsurge in MPS Antibody Discovery partnerships and the progression of its internal therapeutic antibody pipeline